Cargando…
Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula veno...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933747/ https://www.ncbi.nlm.nih.gov/pubmed/29723257 http://dx.doi.org/10.1371/journal.pone.0196791 |
_version_ | 1783320001348894720 |
---|---|
author | Moyer, Bryan D. Murray, Justin K. Ligutti, Joseph Andrews, Kristin Favreau, Philippe Jordan, John B. Lee, Josie H. Liu, Dong Long, Jason Sham, Kelvin Shi, Licheng Stöcklin, Reto Wu, Bin Yin, Ruoyuan Yu, Violeta Zou, Anruo Biswas, Kaustav Miranda, Les P. |
author_facet | Moyer, Bryan D. Murray, Justin K. Ligutti, Joseph Andrews, Kristin Favreau, Philippe Jordan, John B. Lee, Josie H. Liu, Dong Long, Jason Sham, Kelvin Shi, Licheng Stöcklin, Reto Wu, Bin Yin, Ruoyuan Yu, Violeta Zou, Anruo Biswas, Kaustav Miranda, Les P. |
author_sort | Moyer, Bryan D. |
collection | PubMed |
description | Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula venom discovered the Na(V)1.7 inhibitory peptide JzTx-V from the Chinese earth tiger tarantula Chilobrachys jingzhao. The parent peptide displayed nominal selectivity over the skeletal muscle Na(V)1.4 channel. Attribute-based positional scan analoging identified a key Ile28Glu mutation that improved Na(V)1.4 selectivity over 100-fold, and further optimization yielded the potent and selective peptide leads AM-8145 and AM-0422. NMR analyses revealed that the Ile28Glu substitution changed peptide conformation, pointing to a structural rationale for the selectivity gains. AM-8145 and AM-0422 as well as GpTx-1 and HwTx-IV competed for ProTx-II binding in HEK293 cells expressing human Na(V)1.7, suggesting that these Na(V)1.7 inhibitory peptides interact with a similar binding site. AM-8145 potently blocked native tetrodotoxin-sensitive (TTX-S) channels in mouse dorsal root ganglia (DRG) neurons, exhibited 30- to 120-fold selectivity over other human TTX-S channels and exhibited over 1,000-fold selectivity over other human tetrodotoxin-resistant (TTX-R) channels. Leveraging Na(V)1.7-Na(V)1.5 chimeras containing various voltage-sensor and pore regions, AM-8145 mapped to the second voltage-sensor domain of Na(V)1.7. AM-0422, but not the inactive peptide analog AM-8374, dose-dependently blocked capsaicin-induced DRG neuron action potential firing using a multi-electrode array readout and mechanically-induced C-fiber spiking in a saphenous skin-nerve preparation. Collectively, AM-8145 and AM-0422 represent potent, new engineered Na(V)1.7 inhibitory peptides derived from the JzTx-V scaffold with improved Na(V) selectivity and biological activity in blocking action potential firing in both DRG neurons and C-fibers. |
format | Online Article Text |
id | pubmed-5933747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59337472018-05-18 Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V Moyer, Bryan D. Murray, Justin K. Ligutti, Joseph Andrews, Kristin Favreau, Philippe Jordan, John B. Lee, Josie H. Liu, Dong Long, Jason Sham, Kelvin Shi, Licheng Stöcklin, Reto Wu, Bin Yin, Ruoyuan Yu, Violeta Zou, Anruo Biswas, Kaustav Miranda, Les P. PLoS One Research Article Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula venom discovered the Na(V)1.7 inhibitory peptide JzTx-V from the Chinese earth tiger tarantula Chilobrachys jingzhao. The parent peptide displayed nominal selectivity over the skeletal muscle Na(V)1.4 channel. Attribute-based positional scan analoging identified a key Ile28Glu mutation that improved Na(V)1.4 selectivity over 100-fold, and further optimization yielded the potent and selective peptide leads AM-8145 and AM-0422. NMR analyses revealed that the Ile28Glu substitution changed peptide conformation, pointing to a structural rationale for the selectivity gains. AM-8145 and AM-0422 as well as GpTx-1 and HwTx-IV competed for ProTx-II binding in HEK293 cells expressing human Na(V)1.7, suggesting that these Na(V)1.7 inhibitory peptides interact with a similar binding site. AM-8145 potently blocked native tetrodotoxin-sensitive (TTX-S) channels in mouse dorsal root ganglia (DRG) neurons, exhibited 30- to 120-fold selectivity over other human TTX-S channels and exhibited over 1,000-fold selectivity over other human tetrodotoxin-resistant (TTX-R) channels. Leveraging Na(V)1.7-Na(V)1.5 chimeras containing various voltage-sensor and pore regions, AM-8145 mapped to the second voltage-sensor domain of Na(V)1.7. AM-0422, but not the inactive peptide analog AM-8374, dose-dependently blocked capsaicin-induced DRG neuron action potential firing using a multi-electrode array readout and mechanically-induced C-fiber spiking in a saphenous skin-nerve preparation. Collectively, AM-8145 and AM-0422 represent potent, new engineered Na(V)1.7 inhibitory peptides derived from the JzTx-V scaffold with improved Na(V) selectivity and biological activity in blocking action potential firing in both DRG neurons and C-fibers. Public Library of Science 2018-05-03 /pmc/articles/PMC5933747/ /pubmed/29723257 http://dx.doi.org/10.1371/journal.pone.0196791 Text en © 2018 Moyer et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Moyer, Bryan D. Murray, Justin K. Ligutti, Joseph Andrews, Kristin Favreau, Philippe Jordan, John B. Lee, Josie H. Liu, Dong Long, Jason Sham, Kelvin Shi, Licheng Stöcklin, Reto Wu, Bin Yin, Ruoyuan Yu, Violeta Zou, Anruo Biswas, Kaustav Miranda, Les P. Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title | Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title_full | Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title_fullStr | Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title_full_unstemmed | Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title_short | Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V |
title_sort | pharmacological characterization of potent and selective na(v)1.7 inhibitors engineered from chilobrachys jingzhao tarantula venom peptide jztx-v |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933747/ https://www.ncbi.nlm.nih.gov/pubmed/29723257 http://dx.doi.org/10.1371/journal.pone.0196791 |
work_keys_str_mv | AT moyerbryand pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT murrayjustink pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT liguttijoseph pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT andrewskristin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT favreauphilippe pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT jordanjohnb pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT leejosieh pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT liudong pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT longjason pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT shamkelvin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT shilicheng pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT stocklinreto pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT wubin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT yinruoyuan pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT yuvioleta pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT zouanruo pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT biswaskaustav pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv AT mirandalesp pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv |